Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP

Cancer Research

Volumn 57, Issue 24, 1997, Pages 5517-5520

  Jukkola, Arja ^a   Tähtelä, Riitta ^b   Thölix, Eric ^c   Vuorinen, Klaus ^a   Blanco, Guillermo ^a   Risteli, Leila ^a   Risteli, Juha ^a  

^a UNIVERSITY OF OULU   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; PROCOLLAGEN PROPEPTIDE PICP; PROCOLLAGEN PROPEPTIDE PINP; PROCOLLAGENASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COLLAGEN METABOLISM; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ALKALINE PHOSPHATASE; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; PEPTIDE FRAGMENTS; PROCOLLAGEN; SENSITIVITY AND SPECIFICITY;

EID: 0031454187     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Safi, F., Kohler, I., Röttinger, E., and Beger, H-G. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. Cancer (Phila.), 68: 574-582, 1991.
2. Risteli, J., Niemi, S., Kauppila, S., Melkko, J., and Risteli, L. Collagen propeptides as indicators of collagen assembly. Acta Ortop. Scand. 66 (Suppl. 266): 183-188, 1995.
3. Sharp, C. A., Davie, M. W. J., Worsfold, M., Risteli, L., and Risteli, J. Discrepant blood concentrations of type I procollagen propeptides in active Paget disease of bone. Clin. Chem., 42: 1, 1996.
4. Melkko, J., Niemi, S., Risteli, L., and Risteli, J. Radioimmunoassay of the carboxyterminal propeptide of human type 1 procollagen. Clin. Chem., 36: 1328-1332, 1990.
5. Melkko, J., Kauppila, S., Risteli, L., Niemi, S., Haukipuro, K., Jukkola, A., and Risteli, J. Immunoassay for intact aminoterminal propeptide of human type I procollagen. Clin. Chem., 42: 947-954, 1996.
6. Tähtelä, R., Turpeinen, M., Sorva, R., and Karonen, S. L. The aminoterminal propeptide of type 1 procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin. Biochem., 30: 35-40, 1997.
7. 2-terminal propeptides of type I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J. Exp. Med., 179: 405-412, 1994.
8. Smedsrød, B., Melkko, J., Risteli, L., and Risteli, J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via mannose receptor in liver endothelial cells. Biochem. J., 271: 345-350, 1990.
9. Naylor, K. E., Blumsohn, A., Hannon, R. A., Peel, N. F. A.2C and Eastell, R. Different responses of carboxy and amino terminal propeptides of type I procollagen in three clinical models of high bone turnover. J. Bone Miner. Res., 11: 194, 1996.
10. Pucci-Minafra, I., Andrialo, M., Basirilo, L., Aquino, A., Minafra, S., Boutillon, M-M., and Van der Rest, M. Onco-fetal/laminin-binding collagen from colon carcinoma. Detection of new sequences. Biochem. Biophys. Res. Commun., 207: 852-859, 1995.
11. Luparello, C., Sheterline, P., Pucci-Minafra, I., and Minafra, S. A comparison of spreading and motility behaviour of 8701-BC breast carcinoma cells on type I, α I-trimer and type V collagen substrata. Evidence for a permissive effect of type I-trimer collagen on cell locomotion. J. Cell Science. 100: 179-185, 1991.
12. Tähtelä, R., and Tholix, E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PINP, PICP) as markers of metastatic bone disease in breast cancer. Anticancer Res., 16: 2289-2294, 1996.
13. Blomqvist, C., Risteli, L., Risteli, J., Virkkunen, P., and Elomaa, I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br. J. Cancer, 73: 1074-1079, 1996.
14. Kylmälä, T., Tammela, T. L. J., Risteli, L., Risteli, J., Kontturi, M., and Elomaa, I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastasis and has prognostic value in prostate cancer. Br. J. Cancer, 71: 1061-1064, 1995.
15. Elomaa, I., Virkkunen, P., Risteli, L., and Risteli, J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br. J. Cancer, 66: 337-341, 1992.
16. Hakala, M., Risteli, L., Manelius, J., Nieminen, P., and Risteli, J. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann. Rheum. Dis., 52: 866-869, 1993.